Telehealth

Experiences of Clinicians Transitioning to Telemedicine

Citation
Uscher-Pines, L., Sousa, J., Raja, P., Mehrotra, A., Barnett, M., & Huskamp, H. A. (2020). Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. Journal of Substance Abuse Treatment, 108124. Chicago

The COVID-19 pandemic has forced many practitioners to shift their practice online, using telemedicine to treat Opioid Use Disorder. This has allowed for the continuity of essential care whilst adhering to the social distancing guidelines, which protect people from the spread of infection.

Telehealth Learning Series for SUD Treatment and Recovery Support Providers

Created by
ATTC Network

The Addiction Technology Transfer Center (ATTC) Network, the Center for Excellence on Protected Health Information (CoE-PHI), the National Consortium of Telehealth Resource Centers, and the Center for the Application of Substance Abuse Technologies (CASAT) at the University of Nevada - Reno (UNR) partnered to develop this new top tips series.

WHO Guideline: Recommendations on Digital Interventions for Health System Strengthening

Published by
WHO

The key aim of this guideline is to present recommendations based on a critical evaluation of the evidence on emerging digital health interventions that are contributing to health system improvements, based on an assessment of the benefits, harms, acceptability, feasibility, resource use and equity considerations.

Digital Health: A Strategy to Maintain Health Care for People Living with Noncommunicable Diseases during COVID-19

Published by
PAHO
Publication Date

Noncommunicable diseases (NCDs) are the main cause of death and disability worldwide. Effective management of these chronic conditions depends largely on continuous, responsive, accessible, and quality services and successful patient engagement and self-management.

Could a Telehealth Programme Improve Outcomes for Justice-Involved Women?

Evidence has shown that individuals released from prison are at greater risk of drug overdose in the first 2 weeks post-release compared to the general population. After a period of relative abstinence, the tolerance of people who use opioids is greatly reduced and, as a result, they are at particularly high risk of overdosing if they resume use. In order to support this particularly vulnerable group of people, the National Institute of Health is developing